Aster Insights
Lily Paden is a Manager of Commercial Operations at Aster Insights, a bioinformatics company focused on oncology research, since June 2022. Prior experience includes roles at Clean Consulting at UCLA as a Commercial Operations and Strategy Specialist and Business Development Coordinator, where responsibilities involved managing a regional team for Toyota Motor North America and leading projects for the Retail Industry Leaders Association. Lily served as a COP26 Delegate at the UN Climate Change Conference, participated in a climate talk with Dr. Jane Goodall, and produced a webcast series for youth organizations. Additional internships include positions with Forbes Tate Partners, the FDA, David Weiss Law, and California State Senator Henry Stern. Lily holds a Bachelor of Arts in Public Affairs and World Arts & Cultures from UCLA.
This person is not in the org chart
This person is not in any offices
Aster Insights
We believe that personalized medicine starts with a complete view of an individual across their lifetime. Our company was founded in 2006 on the unique principle that informed consent from patients entrusting us with a lifetime connection to their health information, paired with deep partnerships across academia and the life sciences industry, would unlock critical advances in curing cancer. Aster Insights leads the Oncology Research Information Exchange Network (ORIEN®), a consortium of the nation’s leading academic cancer centers that conduct Total Cancer Care®, the world’s largest and longest running observational research study in oncology. TCC® serves as the foundation for novel insights that power oncology breakthroughs. As a long-time innovator in oncology, Aster Insights has world-class expertise in accelerating the life cycle of oncology medical product development. Our solutions are based on scientific and clinical intelligence and strengthened by our unique partnership with patients, academia, and industry. We empower our partners to uncover new targets and biomarkers, enhance cancer detection, deepen our understanding of new treatments, discover new indications, and accelerate clinical trials. Together, we are changing the way cancer is studied, treated, and prevented.